Table 2.

Change from baseline in clinical and patient-reported outcomes among UPA initiators at 6-month follow-up

Characteristic mean change ± SD	All UPA initiators		First-line UPA initiatorsa		TNFi-experienced UPA initiatorsb
	All	Patients remaining on UPA	All	Patients remaining on UPA	All	Patients remaining on UPA
	N = 469	N = 320	N = 87	N = 67	N = 205	N = 132
CDAI	− 8.3 ± 12.9***	− 11.3 ± 13.4***	− 11.7 ± 14.3***	− 13.3 ± 13.7***	− 6.7 ± 12.2***	− 10.0 ± 13.3***
Tender joint count	− 3.6 ± 6.8***	− 5.0 ± 7.3***	− 5.0 ± 7.3***	− 5.9 ± 7.4***	− 2.9 ± 6.6***	− 4.3 ± 7.3***
Swollen joint count	− 2.4 ± 4.8***	− 3.2 ± 5.1***	− 3.6 ± 5.4***	− 3.8 ± 5.1***	− 1.9 ± 4.3***	− 2.9 ± 4.9***
PGA	− 13.0 ± 23.1***	− 17.8 ± 24.6***	− 18.4 ± 25.9***	− 22.8 ± 23.5***	− 9.8 ± 20.8***	− 14.7 ± 23.4***
PtGA	− 9.5 ± 24.1***	− 13.5 ± 26.2***	− 12.7 ± 27.7***	− 13.8 ± 29.0***	− 8.4 ± 21.3***	− 12.7 ± 23.4***
HAQ-DI	− 0.14 ± 0.45***	− 0.20 ± 0.49***	− 0.25 ± 0.56***	− 0.28 ± 0.59***	− 0.07 ± 0.37**	− 0.13 ± 0.42**
Patient-reported pain	− 11.9 ± 25.3***	− 16.7 ± 26.7***	− 14.3 ± 29.6***	− 16.6 ± 30.2***	− 9.5 ± 22.7***	− 14.4 ± 24.5***
Patient-reported fatigue	− 9.8 ± 24.9***	− 13.1 ± 26.4***	− 13.1 ± 27.6***	− 14.5 ± 29.2***	− 7.7 ± 21.4***	− 11.6 ± 22.8***

CDAI Clinical Disease Activity Index, HAQ-DI Health Assessment Questionnaire–Disability Index, PGA Physician’s Global Assessment of Disease Activity, PtGA Patient’s Global Assessment of Disease Activity, SD standard deviation, TNFi tumor necrosis factor inhibitor, UPA upadacitinib

^aFirst-line UPA initiators are a stratum of all UPA initiators

^bThe TNFi-experienced group consists of patients with ≥ 3 months of TNFi experience prior to baseline

*p < 0.05; **p < 0.01; ***p ≤ 0.001 for change at a follow-up versus baseline